Literature DB >> 20643124

Genetic bottlenecks and the hazardous game of population reduction in cell line based research.

David Gisselsson1, David Lindgren, Linda Holmquist Mengelbier, Ingrid Øra, Herman Yeger.   

Abstract

Established tumour cell lines are ubiquitous tools in research, but their representativity is often debated. One possible caveat is that many cell lines are derived from cells with genomic instability, potentially leading to genotype changes in vitro. We applied SNP-array analysis to an established tumour cell line (WiT49). Even though WiT49 exhibited chromosome segregation errors in 30% of cell divisions, only a single chromosome segment exhibited a shift in copy number after 20 population doublings in culture. In contrast, sub-populations derived from single cells expanded for an equal number of population doublings showed on average 5.8 and 8.9 altered segments compared to the original culture and to each other, respectively. Most copy number variants differentiating these single cell clones corresponded to pre-existing variations in the original culture. Furthermore, no sub-clonal variation was detected in any of the populations derived from single cells. This indicates that genetic bottlenecks resulting from population reduction poses a higher threat to genetic representativity than prolonged culture per se, even in cell lines with a high rate of genomic instability. Genetic bottlenecks should therefore be considered a potential caveat in all studies involving sub-cloning, transfection and other conditions leading to a temporary reduction in cell number.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20643124     DOI: 10.1016/j.yexcr.2010.07.010

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

Authors:  Shunqiang Li; Dong Shen; Jieya Shao; Robert Crowder; Wenbin Liu; Aleix Prat; Xiaping He; Shuying Liu; Jeremy Hoog; Charles Lu; Li Ding; Obi L Griffith; Christopher Miller; Dave Larson; Robert S Fulton; Michelle Harrison; Tom Mooney; Joshua F McMichael; Jingqin Luo; Yu Tao; Rodrigo Goncalves; Christopher Schlosberg; Jeffrey F Hiken; Laila Saied; Cesar Sanchez; Therese Giuntoli; Caroline Bumb; Crystal Cooper; Robert T Kitchens; Austin Lin; Chanpheng Phommaly; Sherri R Davies; Jin Zhang; Megha Shyam Kavuri; Donna McEachern; Yi Yu Dong; Cynthia Ma; Timothy Pluard; Michael Naughton; Ron Bose; Rama Suresh; Reida McDowell; Loren Michel; Rebecca Aft; William Gillanders; Katherine DeSchryver; Richard K Wilson; Shaomeng Wang; Gordon B Mills; Ana Gonzalez-Angulo; John R Edwards; Christopher Maher; Charles M Perou; Elaine R Mardis; Matthew J Ellis
Journal:  Cell Rep       Date:  2013-09-19       Impact factor: 9.423

2.  A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.

Authors:  S Bahram Bahrami; Beryl A Hatton; Richard A Klinghoffer; Jason P Frazier; Alicia Moreno-Gonzalez; Andrew D Strand; William S Kerwin; Joseph R Casalini; Derek J Thirstrup; Sheng You; Shelli M Morris; Korashon L Watts; Mandana Veiseh; Marc O Grenley; Ilona Tretyak; Joyoti Dey; Michael Carleton; Emily Beirne; Kyle D Pedro; Sally H Ditzler; Emily J Girard; Thomas L Deckwerth; Jessica A Bertout; Karri A Meleo; Ellen H Filvaroff; Rajesh Chopra; Oliver W Press; James M Olson
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

3.  The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis.

Authors:  Linda Holmquist Mengelbier; Simon Lindell-Munther; Hiroaki Yasui; Caroline Jansson; Javanshir Esfandyari; Jenny Karlsson; Kimberly Lau; Chi-Chung Hui; Daniel Bexell; Sevan Hopyan; David Gisselsson
Journal:  J Pathol       Date:  2018-11-29       Impact factor: 7.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.